Acinetobacter baumannii Gastrointestinal Colonization Is Facilitated by Secretory IgA Which Is Reductively Dissociated by Bacterial Thioredoxin A

Patrick M. Ketter,a* Jieh-Juen Yu,a,b M. Neal Guentzel,a,b Holly C. May,a Rishein Gupta,a,b Mark Eppinger,a,b Karl E. Klose,a,b J. Seshu,a,b James P. Chambers,a,b Andrew P. Cap,c Bernard P. Arulanandam,a,b

a Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA
b South Texas Center for Emerging Infectious Disease, University of Texas at San Antonio, San Antonio, Texas, USA
c Coagulation and Blood Research Program, U.S. Army Institute for Surgical Research, JBSA Fort Sam Houston, Texas, USA

ABSTRACT

Multidrug-resistant Acinetobacter baumannii is among the most common causes of infectious complications associated with combat-related trauma in military personnel serving overseas. However, little is currently known about its pathogenesis. While the gastrointestinal (GI) tract has been found to be a major reservoir for A. baumannii, as well as to potentially contribute to development of multidrug resistance, no studies have addressed the mechanisms involved in gut colonization. In this study, we address this critical gap in knowledge by first assessing the interaction between secretory IgA (SIgA), the principal humoral immune defense on mucosal surfaces, and the A. baumannii clinical isolate Ci79. Surprisingly, SIgA appeared to enhance A. baumannii GI tract colonization, in a process mediated by bacterial thioredoxin A (TrxA), as evidenced by reduction of bacterial attachment in the presence of TrxA inhibitors. Additionally, a trxA targeted deletion mutant (ΔtrxA) showed reduced bacterial burdens within the GI tract 24 h after oral challenge by in vivo live imaging, along with loss of thiolreductase activity. Surprisingly, not only was GI tract colonization greatly reduced but the associated 50% lethal dose (LD50) of the ΔtrxA mutant was increased nearly 100-fold in an intraperitoneal sepsis model. These data suggest that TrxA not only mediates A. baumannii GI tract colonization but also may contribute to pathogenesis in A. baumannii sepsis following escape from the GI tract under conditions when the intestinal barrier is compromised, as occurs with cases of severe shock and trauma.

IMPORTANCE Acinetobacter baumannii is an emerging bacterial pathogen recently classified as a serious threat to U.S. and global health by both the Centers for Disease Control and Prevention and the World Health Organization. It also is one of the leading causes of combat-related infections associated with injured military personnel serving overseas. Little is known regarding mechanisms of gastrointestinal tract colonization despite this site being shown to serve as a reservoir for multidrug-resistant (MDR) A. baumannii isolates. Here, we establish that secretory IgA, the major immunoglobulin of mucosal surfaces, promotes A. baumannii GI tract colonization via bacterial thioredoxin A as evidenced through significant reduction in colonization in IgA-deficient animals. Additionally, bacterial colonization and mortality were significantly reduced in animals challenged with a thioredoxin A-deficient A. baumannii mutant. Combined, these data suggest that thioredoxin A is a novel virulence factor, for which antithioredoxin therapies could be developed, for this important multidrug-resistant pathogen.
Acinetobacter baumannii is an opportunistic pathogen that has become a significant concern for clinicians due to its high prevalence of multidrug resistance (1–5). A. baumannii isolates are intrinsically resistant to many antibiotics due to a reduced repertoire of membrane porins, naturally expressed beta-lactamases, and various efflux pumps (6). Acquired antibiotic resistance, through horizontal gene transfer, has only exacerbated the problem (1, 2, 4, 7–12). Currently, the highly toxic antibiotic colistin, which targets bacterial membranes, is often used as a treatment of last resort (5, 13, 14). Furthermore, the gastrointestinal (GI) tract colonization has been linked to development of antibiotic resistance in A. baumannii (15), presumably due to close proximity of the organism to the enormous numbers and varieties of bacteria therein, allowing direct transfer of antibiotic resistance plasmids through bacterial conjugation (16, 17). However, while the GI tract is a common site of colonization (4, 15, 18–21), there is currently a gap in our understanding of the mechanisms facilitating this colonization.

Secretory IgA (SIgA) contributes to GI tract homeostasis and protection against pathogens along mucosal surfaces (22–24). SIgA is transported across mucosal epithelia by polymeric immunoglobulin receptor (pIgR) and is comprised of a secretory component (SC) covalently bound to the Fc regions of dimeric IgA (25, 26). Both SC and SIgA interact with various antigens in a nonspecific manner due to protein glycosylation associated with both molecules (22). Additionally, SC is thought to protect the dimeric IgA molecule from both host and bacterial proteases (22); however, bacteria have developed IgA-specific proteases (27–30) as well as thiol-specific reductases produced in response to this immunoglobulin (31). Given the prevalence of A. baumannii as a mucosal pathogen, it is highly likely that it would possess similar mechanisms, although none have been described.

In this study, we set out to specifically address this critical gap in our understanding of A. baumannii pathogenesis. We found not only that SIgA contributes to A. baumannii colonization in a murine oral GI challenge model but that the organism reduces the disulfide bonds of SIgA, causing separation of SC from dimeric IgA in a process mediated by secreted bacterial thioredoxin A (TrxA).

RESULTS

Contribution of SIgA to A. baumannii GI tract colonization. Since SIgA is the primary immunoglobulin associated with mucosal surfaces, including the GI tract (22), we set out to determine if it was protective against A. baumannii GI tract colonization and infection. We first orally challenged wild-type (WT) C57BL/6 and IgA−/− mice with a PSVue-794-labeled A. baumannii clinical isolate, designated strain Ci79, that we previously found to be virulent in a mouse intraperitoneal sepsis model (32). Surprisingly, in vivo live imaging of challenged mice revealed significantly (P < 0.05) enhanced A. baumannii clearance 24 h postchallenge in the absence of IgA (Fig. 1A). We subsequently humanely euthanized and collected GI tracts 24 h postchallenge from IgA−/− and WT animals for ex vivo imaging (Fig. 1B). Again, while minimal signal was detected from GI tracts collected from IgA−/− mice, fluorescence was observed throughout WT mouse GI tracts. Loss of signal in IgA−/− mice could not be explained by bacterial dissemination from the GI tract, as no fluorescence was observed in surrounding tissues (i.e., liver, spleen, and kidney).

We next sought to determine how IgA might contribute to, rather than protect against, GI tract colonization. Utilizing an ex vivo intestinal attachment assay, sections of small intestine were obtained from humanely euthanized 6- to 10-day-old mice. While lack of IgA is reported to alter intestinal microbiota (23), suckling mice lack adult microbiota, thus minimizing this confounding influence (23, 33). Additionally, although suckling WT mice do not yet produce IgA, they receive maternal IgA in milk (23). Following incubation of intestinal sections in suspensions of A. baumannii Ci79, we
observed a nearly 80% reduction in bacterial attachment \((P < 0.0001)\) in the absence of IgA (Fig. 2). We then repeated these experiments using sections of small intestine collected from humanely euthanized adult mice with similar results, suggesting that, in contrast to IgA, intestinal microbiota has little effect on \textit{A. baumannii} attachment (Fig. 2).

While IgA\(^{-/-}\) mice lack IgA production, they still produce functional plgR \((34, 35)\). Furthermore, plgR is constantly transcytosed from the basal membrane to the luminal surface of mucosal epithelial cells, where it is cleaved to produce free SC (working

---

**FIG 1** Effect of SIgA on \textit{A. baumannii} clearance from the GI tract. Clearance of PSVue-794-labeled \textit{A. baumannii Ci79} was assessed in WT (white circles) and IgA\(^{-/-}\) (gray squares) mice over 24 h by in vivo live imaging (A). Representative images of mice following challenge are shown above the graph for each group and observation point. Ex vivo assessment of organs (Kd, kidney; St, stomach; L, liver; Sp, spleen; Sb, small bowel; C, cecum; Lb, large bowel) from WT (left) and IgA\(^{-/-}\) (right) mice following challenge with PSVue-794-labeled \textit{A. baumannii Ci79} was performed 24 h after challenge (B). Error bars represent ± standard deviations (SD). Statistical differences were determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons (*, \(P < 0.01\); **, \(P < 0.001\)).

**FIG 2** Effect of SIgA on \textit{A. baumannii} attachment to the intestinal mucosa. Intestinal attachment was assessed in both adult and infant mice. The small intestine was dissected from WT and IgA\(^{-/-}\) mice. Small intestines were cut into sections measuring approximately 1 cm in length, and the intestinal lumen was exposed prior to incubation with \textit{A. baumannii Ci79} \((1 \times 10^8 \text{ CFU/ml})\) for 30 min. After exhaustive washing to remove free bacteria, sections were homogenized and bacteria were enumerated by dilution plating. Error bars represent ± SD. Statistical differences were determined by the Welch t test (**, \(P < 0.001\)); (***, \(P < 0.0001\)).
model; see Fig. S1, left, in the supplemental material) (25). Binding of immunoglobulin (IgA or IgM) simply speeds the process of transcytosis (Fig. S1, middle) (25). Therefore, IgA−/− mice still exhibit free SC in mucous linings. Interestingly, while IgA−/− mice appear to clear the fluorescent bacteria by 24 h postchallenge, clearance was even more rapid in pIgR−/− mice, with fluorescent signal becoming negligible within 8 h (Fig. 3). These data suggest that free SC, rather than intact SIgA, is the primary mediator of A. baumannii GI colonization (Fig. S1, right).

*A. baumannii* dissociated secretory component from SIgA. As many GI tract-associated bacteria produce IgA-specific proteases (27–30), we sought to assess the direct interaction between SIgA and *A. baumannii* by incubating Ci79 with 50 μg/ml of either human serum IgA or SIgA overnight in Dulbecco’s Modified Eagle’s Medium (DMEM). As expected, multiple bands were observed, indicating degradation of the immunoglobulin (Fig. 4A). However, Western blot analysis revealed clearly defined bands associated with α-heavy chain (serum IgA only), λ-light chain, and SC (SIgA only) with little smearing, indicating the absence of proteolysis (Fig. 4A). To confirm, we inoculated bacteria on LB agar supplemented with 2% skim milk to detect secreted protease (36). As expected, Ci79 exhibited no protease activity, as evidenced by lack of clearing around the bacteria (Fig. 4B). As SC is bound to dimeric IgA by disulfide bonds, release of SC from SIgA may be mediated via reductive processes. To test this possibility, we grew Ci79 (Fig. 4C), along with a variety of other *A. baumannii-Acinetobacter calcoaceticus* complex isolates (Fig. S2), in M9 minimal medium (M9MM) supplemented with 1 mM membrane-impermeant dithionitrobenzoic acid (DTNB) to detect secreted reductase activity (8, 37). DTNB was reduced to 2-nitro-5-thiobenzoic acid (TNB; yellow color) in the presence of the bacteria in a fashion similar to the positive reduction control β-mercaptoethanol (βME; a strong thiol-reducing agent). These data suggest that *A. baumannii* may break down SIgA via reductive processes targeting the disulfide bonds within the immunoglobulin.

We previously genome sequenced and annotated a series of *A. baumannii* isolates, including strain Ci79 (38). Utilizing BLAST2GO analysis software, we assigned gene ontology terms to annotated genes and identified those encoding proteins and enzymes involved in reductive processes (GO:005514), specifically disulfide-reducing enzymes (GO:0004791 and/or GO:0015035). These criteria identified 9 genes with characteristics necessary for reduction of disulfide bonds within SIgA (Table 1). We then incubated *A. baumannii* Ci79 with or without 100 μg/ml human SIgA for 1, 2, or 6 h and performed transcriptome RNA sequencing (RNA-seq) analysis. Although total gene expression was modulated at all intervals (Fig. 5A), significant modulation of disulfide-
reducing proteins was observed only at 2 h. Furthermore, only trxA mRNA expression was significantly upregulated following SIgA exposure (Fig. 5B).

**Generation of an A. baumannii thioredoxin A-null mutant.** We next generated a trxA targeted gene deletion mutant (ΔtrxA) in WT A. baumannii Ci79. A complemented strain, ΔH9004trxA, was also generated from ΔH9004trxA, restoring TrxA protein expression. Generation of the ΔtrxA strain was confirmed by Southern blot analysis showing the predicted 3.4-kb fragment resulting from HindIII restriction digest of genomic DNA, compared to the 2.8-kb fragment observed with WT DNA (Fig. 6A and B). Restriction digest of WT and ΔtrxA genomic DNA with XbaI also resulted in predicted DNA fragments (Fig. 6A and B), further confirming successful incorporation of the erythromycin resistance

**FIG 4** Interaction of A. baumannii with SIgA. Supernatants were obtained from A. baumannii Ci79 cultures incubated with medium alone (lane 1), serum IgA (lane 2), and SIgA (lane 3) and assessed by nonreducing SDS-PAGE (A). Gels were assessed by silver staining (far left; molecular marker sizes in kDa are shown) and Western blotting targeting the α-heavy chain (left center), λ-light chain (right center), or secretory component (far right). A. baumannii Ci79 was further assessed for secreted proteolytic activity by the development of a transparent zone on skim milk agar (B) and disulfide-reducing activity by converting DTNB to yellow TNB (C). P. aeruginosa was used as a positive protease control. β-mercaptoethanol was used as a positive reduction control. Error bars represent ±SD. Statistical differences were determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons (***, P < 0.0001).

**TABLE 1** Disulfide reductase enzymes

| Gene identifier | Gene symbol | Gene name                               |
|-----------------|-------------|-----------------------------------------|
| M212_0027       | dsbA        | dsbA oxidoreductase                     |
| M212_0318       | grnC        | Dithiol-disulfide reductase             |
| M212_0534       | trxA        | Thioredoxin                             |
| M212_0650       | grxD        | Glutaredoxin                            |
| M212_2314       |              |                                        |
| M212_2668       |              |                                        |
| M212_3532       |              |                                        |
| M212_3989       |              |                                        |
| M212_4220       | trxB        | Thioredoxin reductase                   |

*BLAST homology only; not annotated.*
gene (ermR) in place of trxA via homologous recombination. A similar homologous recombination strategy was employed to generate the trxA-complemented strain (H9004\textsubscript{trxAc}) with trxA derived from A. baumannii Ci77 containing a synonymous small nucleotide polymorphism (SNP), resulting in loss of a SalI restriction site and yet remaining 100% identical to that of the Ci79 strain on an amino acid level. While putative trxA-complemented strains were selected based on restoration of DTNB reduction, after several transformation attempts a single stable complement clone was obtained. However, Southern blot analysis suggested that complementation did not result in integration into the chromosome as expected, as evident by the presence of both the 3.4-kb fragment observed in the H9004\textsubscript{trxA} deletion mutant and an additional band approximately 5 kb in size following HindIII digest (Fig. 6B). Similarly, XbaI digest produced both the 5.1-kb fragment associated with the H9004\textsubscript{trxA} mutant and a fragment approximately 10 kb in size. Whole-genome sequencing failed to pinpoint an integration site, suggesting that the H9004\textsubscript{trxAc} strain may maintain trxA ectopically on a plasmid. Despite this, Southern blot analysis suggested that complementation did not result in integration into the chromosome as expected, as evident by the presence of both the 3.4-kb fragment observed in the ΔtrxA deletion mutant and an additional band approximately 5 kb in size following HindIII digest (Fig. 6B). Similarly, XbaI digest produced both the 5.1-kb fragment associated with the ΔtrxA mutant and a fragment approximately 10 kb in size. Whole-genome sequencing failed to pinpoint an integration site, suggesting that the ΔtrxA\textsuperscript{c} strain may maintain trxA ectopically on a plasmid. Despite this, the presence of the Ci77 trxA gene in the ΔtrxA\textsuperscript{c} strain was confirmed through SalI digest of PCR-amplified trxA (Fig. 6C). PCR targeting trxA in the ΔtrxA mutant resulted in a 971-bp product corresponding to the erythromycin resistance cassette (Fig. 6C). SalI digestion of the trxA PCR product from WT Ci79 produced fragments of 178 bp and 199 bp in length (seen in Fig. 6C as a single band of approximately 200 bp). However, cleavage was not observed with the ΔtrxA\textsuperscript{c} strain, resulting in a 370-bp band.

FIG 5 RNA-seq analysis of A. baumannii gene expression following SIgA stimulation. Global gene expression was assessed by RNA-seq in A. baumannii treated with SIgA and compared to untreated controls at 1 (top), 2 (middle), and 6 (bottom) h posttreatment (A). Gene expression of 9 thiol-reducing enzymes involved in thiol-reducing processes was directly assessed (B). Red data points and labels represent trxA gene expression. Error bars represent ±SD. Statistical differences were determined by Student’s t test (*, *P < 0.0001).
mented strain as well. Most importantly, the lack of TrxA protein expression in the ΔtrxA mutant and subsequent restoration in the ΔtrxAΔ strain were confirmed by Western blot analysis (Fig. 6D).

Deletion of trxA had unexpected effects on A. baumannii growth in LB medium. We observed an increase in the lag phase of growth associated with ΔtrxA compared to WT and ΔtrxAΔ isolates (Fig. 7A). However, log-phase growth appeared largely unaffected. Additionally, ΔtrxA colonies were smaller than WT (Fig. 7B). Similar observations have been reported in yeast following disruption of thioredoxin genes and were attributed to an inability to reduce glutathiolated proteins during transition from lag- to log-phase growth (39). While the presence of secreted reductase enzymes has been reported in the extracellular proteome (40), the inability to reduce membrane-impermeant DTNB indicated that secreted redox activity was greatly reduced following deletion of trxA (Fig. 7C). These data suggest not only that A. baumannii secretes TrxA but that this protein is the primary thiol-reducing protein responsible for reduction of disulfide bonds in the extracellular environment. Although lacking a typical amino-terminal signal sequence, thioredoxins have been shown to be secreted by Helicobacter pylori (31) as well as various normal and tumor mammalian cells via a nonclassical pathway (41, 42).

Effect of thioredoxin A on GI tract colonization. An ex vivo intestinal bacterial attachment assay and in vivo oral bacterial challenge experiments were used to elucidate the role of TrxA in A. baumannii colonization in the GI tract. Two thioredoxin inhibitors, DTNB (a competitive inhibitor of disulfide reductase enzymes [43]) and 1-methylpropyl-2-mercaptoimidazolyl disulfide (PX-12; an irreversible thioredoxin inhibitor [44]), were shown to block the WT Ci79 mediated-release of SC from SlgA...
Additionally, Ci79 attachment to excised intestinal sections was significantly reduced in the presence of these two TrxA inhibitors (Fig. 8B). For the in vivo study, mice were challenged orally with PSVue-794-labeled bacteria to monitor bacterial clearance from the GI tract via in vivo live imaging. A significant decrease in bacterial colonization of the GI tract was evidenced by both diminished fluorescent intensity and reduced fecal shedding of the \( H9004 \) \( trxA \) strain by 24 h relative to mice challenged with either the WT or \( H9004 \) \( trxAc \) strain (Fig. 9). These results demonstrated the important role of TrxA in \( A. \) baumannii GI colonization. Loss of TrxA also resulted in decreased mortality following systemic \( A. \) baumannii infection. As shown in Fig. S3, while all mice succumbed to infection following a 2-LD\(_{50}\) (50% lethal dose; \( 1 \times 10^6 \) CFU) intraperitoneal challenge with both WT and \( H9004 \) \( trxAc \) strains, 100% of mice challenged with equivalent

![Figure 7](https://example.com/fig7.png)

**FIG 7** Complementation of \( CI79 \) \( \Delta \)trxA with \( CI77 \) trxA gene rescues phenotypic defects. The WT \( CI79 \), \( \Delta \)trxA, and \( \Delta \)trxA\(^c\) bacteria were characterized for growth in LB broth (A), colony size on LB agar (B), DTNB-reducing activity (C), and use of DTNB for growth (D). Error bars represent ±SD. Statistical differences were determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons (*, \( P < 0.01 \); **, \( P < 0.001 \); ***, \( P < 0.0001 \); ****, \( P < 0.00001 \); ns, not significant).

![Figure 8](https://example.com/fig8.png)

**FIG 8** Contribution of thioredoxin to \( A. \) baumannii mucosal surface attachment. Reduction of SIgA by WT \( CI79 \) bacteria was assessed in the presence or absence of pan-protease inhibitor (PI) and TrxA inhibitors (DTNB and PX-12) (A). Release of secretory component (SC) was assessed by Western blot analysis as a percentage of the fully reduced control (β-mercaptoethanol). Inhibition of \( CI79 \) attachment to excised mouse intestine sections by DTNB and PX-12 was assessed by dilution plating, and bacterial attachment is expressed as a percentage compared to untreated control. Statistical differences were determined by Student's t test compared to untreated control (B) (*, \( P < 0.05 \)).
doses of the ΔtrxA strain survived. In fact, mortality was observed only after administration of >5 × 10⁶ CFU/mouse, a nearly 100-fold increase in the associated LD₅₀.

**DISCUSSION**

Data presented here suggest that SlgA contributes to A. baumannii colonization of the GI tract. We observed a significant reduction in bacterial colonization (Fig. 1 and 3) and a nearly 80% decrease in bacterial attachment in the absence of SlgA (Fig. 2). While we observed breakdown of SlgA by A. baumannii (Fig. 4A), initially suggesting possible proteolysis similar to that described with Clostridium spp. (27), the absence of secreted protease activity (Fig. 4B) in combination with observed secretion of thiol-reducing activity (Fig. 4C) suggested that breakdown was mediated instead by reduction of disulfide bonds within SlgA by a thiol-reducing enzyme. Indeed, prior studies have demonstrated the importance of disulfide bonds to SlgA structural stability (45). Supporting this hypothesis, Helicobacter pylori has been reported to secrete TrxA in response to host immunoglobulin for protection from the host immune system (31). Similarly, our RNA-seq analysis specifically demonstrated upregulation of trxA gene expression in A. baumannii following exposure to SlgA (Fig. 5). While thiol reductase activity was detected in the absence of SlgA, upregulation of trxA gene expression suggests that A. baumannii mounts a similar response to H. pylori. Additionally, inhibition of TrxA resulted in ablation of SlgA reduction and a significant reduction in A. baumannii attachment to the intestinal mucosal surface (Fig. 8).

Thioredoxin has been implied to have many cellular functions beyond protection from oxidative stressors, including cell cycle regulation and protein folding/transportation (46). Utilizing a tandem affinity purification (TAP)-tagged Escherichia coli TrxA, Kumar et al. (46) identified 80 TrxA-associated proteins involved in distinct cellular processes that include transcription regulation, cell division, energy transduction, and...
several biosynthetic pathways. Similarly, in our study, the loss of TrxA expression resulted in a multitude of effects on the bacterium, including decreased colony size and an extended lag phase (Fig. 7B). Additionally, lack of TrxA protein expression ablated secreted disulfide reductase activity (Fig. 7C). Mice challenged with *A. baumannii* Ci79 ΔtrxA also survived challenge doses nearly 100-fold higher than the LD$_{50}$ associated with the WT Ci79 strain (see Fig. S3 in the supplemental material) and exhibited significantly increased mutant clearance and decreased fecal shedding (Fig. 9). As complementation restored all WT phenotypes, our data indicate two potential functions of TrxA secreted by *A. baumannii* with respect to colonization of mucosal surfaces. As shown in our working model of *A. baumannii* GI tract colonization (Fig. S1), TrxA secreted by *A. baumannii* reduces disulfide bonds within the immediate microenvironment, including those within SLgA, neutralizing protective barrier functions associated with the immunoglobulin. Second, reduced SLgA provides *A. baumannii* a means of colonizing mucous layers though increasing concentrations of available free SC within the mucous lining. However, the mechanism(s) of SC-mediated *A. baumannii* GI colonization remains elusive. While reduction of SLgA by TrxA clearly contributes to this process, immunoglobulin may not be the only target of the protein as thioredoxin also has been implicated in bacterial mucosal colonization by other mechanisms. For example, *Helicobacter pylori* uses secreted thioredoxin to reduce mucin molecules to their monomeric form, decreasing mucus viscosity and allowing the organism to colonize as well as facilitate migration to the epithelial surface (31). Deletion of either the TrxA or TrxC gene in *H. pylori* impairs the organism’s ability to colonize the stomach following oral bacterial inoculation (47).

While TrxA has now been identified as a potential mechanism by which *A. baumannii* colonizes the GI tract, the viability of this target for chemotherapy may be questioned due to apparent widespread distribution of TrxA gene homology among commensal bacterial species. However, the use of *A. baumannii*-specific TrxA as a subunit vaccine may provide at least partial protection while preventing species-nonspecific inhibition. Additionally, attenuation resulting from loss of TrxA expression by *A. baumannii* may allow the ΔtrxA mutant to serve as a useful live-attenuated vaccine strain. Current studies by our laboratory are focused on evaluating this possibility, as immunization with the ΔtrxA mutant provided marked protection against systemic infection with the WT strain (48).

**MATERIALS AND METHODS**

**Ethics statement.** All animal experiments were performed in compliance with the Animal Welfare Act, the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide for the Care and Use of Laboratory Animals (49). All animal work was carried out under approved protocol MU070-10/14A0 in accordance with guidelines set forth by the University of Texas at San Antonio Institutional Animal Care and Use Committee (IACUC) and the Institutional Biosafety Committee (IBC).

**Bacterial strains.** *A. baumannii* clinical isolate strain Ci79 was used in all experiments unless otherwise stated. Plasmids were cloned into either *E. coli* ATCC 25922 or *Pseudomonas aeruginosa* ATCC 27317 (American Type Culture Collection, Manassas, VA). Bacteria were grown at 37°C to desired concentrations based on optical density of broth cultures measured at 600 nm (OD$_{600}$).

**Mice.** Eight- to 10-week-old pathogen-free C57BL/6 mice were purchased from Charles River Laboratories (Frederick, MD). Homozygous *plgR* knockout mice (*plgR$^{-/-}$; B6.129P2-*PlgR*tm1Fejo/Mmmh) were obtained from the Mutant Mouse Resource and Research Center (University of Missouri, Columbia, MO). Male *plgR$^{-/-}$ mice were bred with female WT C57BL/6 mice, producing litters consisting of 100% heterozygous offspring (*plgR$^{+/+}$), ensuring that resulting offspring received SLgA in breast milk (see Fig. S4 in the supplemental material). Female *plgR$^{+/+}$ (SLgA-producing) offspring were backcrossed with homozygous *plgR$^{-/-}$ mice, producing litters of approximately 50% *plgR$^{+/+}$ and 50% *plgR$^{-/-}$ mice. Genotyping was performed by PCR utilizing the following primer combinations: *plgRKO_FW/*plgRKO_RV* (Table 2) amplifying the mutant allele (150 bp) and *plgRWT_FW/*plgRWT_RV* (Table 2) amplifying the WT allele (226 bp). PCR was performed with GenScript *Taq* polymerase (GenScript, Piscataway, NJ) per the manufacturer’s instructions. Homozygous IgA$^{-/-}$ mice (34) were bred in-house for all experiments.

**In vivo live imaging.** Stocks of *A. baumannii* clinical isolate Ci79 (200-ul aliquots) were prepared from log-phase growth and frozen at −80°C in LB broth supplemented with 10% glycerol. Titers of frozen stocks were determined on three separate days and averaged. Prior to challenge, bacteria were thawed and pelleted at 3,000 × g. Bacterial pellets were suspended in PSVue-794 ( Molecular Targeting Tech-
TABLE 2 Primers used in this study

| Primer name | Sequencea | Use |
|-------------|-----------|-----|
| Thio-1      | ACCGAGATCCATGTCCGACATTTGA | Recombinant protein |
| Thio-2      | ACCGTCGACTCTAAAGGGTTTCTGCAAAT | Recombinant protein |
| Up_Fw       | GCCGTCCAGCCCATATTACACCATATTG | SOE-PCR |
| Up_Rv       | GGATCCACTACTGGCCGGTACGTTGCTTCAATT | SOE-PCR |
| Down_Rv     | GGATCCGCACCAGTATGGGACGAAATGTATTAAAG | SOE-PCR |
| TrxA_Rv     | CTAAAAATTGGAGCCGTACC | Screening |
| TrxA-fw     | CGATTTTTCTACGTAAATGTACGGTAG | Screening |
| ABC_Fw      | GTCTGAAACAGGTACGCAGTA | Strain typing |
| ABC_Rv      | GGTGGGTTCCTCACAGCAGA | Strain typing |
| pIgRKO_FW   | GAACATCTGTGCTTGTGTTCC | pIgR genotyping |
| pIgRKO_Rv   | TCCAGACTCTGCTTGGGAAA | pIgR genotyping |
| pIgRWT_FW   | GAACATCTGTGCTTGTGTTCC | pIgR genotyping |
| pIgRWT_Rv   | CTGCACCATATCCTTTC | pIgR genotyping |

aBoldface indicates restriction enzyme cleavage sites. Underlining indicates complementary sequence.

nologies, Inc., West Chester, PA) at a concentration of approximately 10 µl per 106 CFU and placed on ice for 45 min. Bacteria were washed in TES buffer (5 mM TES [N-tris(hydroxymethyl)-methyl-2-aminoethane sulfonic acid], 145 mM NaCl, pH 7.4) and brought up to a concentration of 5 × 106 CFU/ml. Once prepared, mice were anesthetized by isoflurane inhalation and abdominal fur was washed using hair removal cream. Mice were challenged by oral gavage with 100 µl PSVue-794-stained bacteria and monitored at indicated intervals utilizing the Carestream MS FX Pro in vivo imaging system (Bruker, Billerica, MA). At 24 h, mice were humanely euthanized and organs were excised for ex vivo imaging. Image analysis and annotation were performed using Carestream analysis software.

Ex vivo intestinal attachment assay. Bacterial attachment to intestinal mucosa was performed as described by Guentzel and Berry (33), with some modifications. Briefly, bacteria were washed once in sterile phosphate-buffered saline (PBS) and diluted to a concentration of 1 × 106 CFU/ml. The small intestine was dissected from humanely euthanized 6- to 10-day-old infant mice, unless otherwise stated, and cut into sections measuring approximately 1 cm in length. Using fine scissors, the intestinal lumen was exposed and sections were placed in the bacterial suspension for 30 min with regular agitation. In some experiments, the bacterial suspensions were prepared with either 1 mM DTNB (Fisher Scientific, Pittsburgh, PA) or 15 g/ml PX-12 (Tocris, Minneapolis, MN). Sections were placed in 500 volumes of sterile PBS and inverted 7 times. This was repeated once before sections were placed in 200 volumes of sterile PBS and allowed to soak for 5 min. Each section was transferred to 10 ml sterile PBS and homogenized. Dilution plating was performed on LB agar containing 50 µg/ml chloramphenicol and 10 µg/ml cycloheximide to inhibit growth of resident microbiota.

Analysis of secreted protease activity. Bacterial suspensions of either A. baumannii or P. aeruginosa were prepared from log-phase growth (OD600 of 0.7), and 10 µl was spotted onto LB agar supplemented with 2% skim milk.

Disulfide reductase assay. Indicated bacteria were grown at 37°C to an OD600 of 0.7. Each strain was pelleted at 3,000 × g and washed three times in M9MM (48 mM Na2HPO4, 167 mM KH2PO4, 8.5 mM NaCl, 1.9 mM MgCl2, 2 mM NH4Cl, 0.4% glucose). Bacterial pellets were suspended in either sterile M9MM alone or M9MM supplemented with 1 mM DTNB and grown for 24 h at 37°C, at which point supernatants were collected. Reductase activity was observed through yellow color development at 450 nm.

SlgA reduction assay. Bacterial broth cultures were pelleted at 3,000 × g for 5 min, washed three times in equal volumes of sterile DMEM (Life Technologies, Inc., Grand Island, NY) to remove trace amounts of reducing substances, and suspended in an equal volume of sterile DMEM. In parallel, lyophilized SlgA from human colostrum or serum IgA from human plasma (Athens Research, Athens, GA) was diluted to a concentration of 100 µg/ml in sterile DMEM. Once prepared, 250 µl of the bacterial suspension was combined with 250 µl SlgA or serum IgA and incubated for 24 h. For experiments examining inhibition of SlgA reduction, individual preparations of SlgA were prepared containing either 2 mM DTNB or 30 µg/ml PX-12, resulting in final concentrations of 1 mM DTNB and 15 µg/ml PX-12, respectively, and incubation was reduced from 24 hours to 2 hours. Supernatants were collected and mixed 1:4 in native sample buffer (40% glycerol, 250 mM Tris-HCl, 0.015% bromphenol blue) before being subjected to nonreducing SDS-PAGE on a 12% polyacrylamide gel. Following electrophoresis, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA) for Western blot analysis using goat anti-human SC primary antibody (1:1,000 dilution; Sigma-Aldrich, St. Louis, MO) followed by rabbit anti-goat polyclonal anti-human SC primary antibody (1:1,000 dilution; Sigma-Aldrich, St. Louis, MO). Blotted membranes were imaged for bands using an ImageQuant LAS 4000 (GE Healthcare, Buckinghamshire, UK).
Technologies, Waltham, MA). Enriched bacterial mRNA was processed and subjected to RNA sequencing by Illumina HiSeq (Illumina, San Diego, CA) at the UT Southwestern Genomics Resource Core. Expression analysis was performed utilizing the CLCbio Genomics Workbench. Gene ontology annotation was performed on *A. baumannii* strain C179 (G572039789) utilizing BLAST2GO software, and genes were segregated based on functional classification.

**Generation of recombinant *A. baumannii* thioredoxin and anti-TrxA antibody.** *A. baumannii* trxA was amplified from genomic DNA obtained from *A. baumannii* C177 using primers Thio-1 and Thio-2 (Table 2) and subsequently cloned into pMAL-C2X, resulting in incorporation of a 3’ maltose binding protein (MBP) tag. Rosetta-gami *E. coli* cells were transformed with the pMAL-trxA construct for generation of an MBP-TrxA fusion protein (rTrxA). rTrxA expression in the transformed *E. coli* was induced in the presence of glucose (final concentration, 2 g/liter) and IPTG (isopropyl-β-D-thiogalactopyranoside; 1 mM) overnight in a 16°C shaking incubator. Isolation of rTrxA by amylose affinity chromatography was conducted according to the manufacturer’s recommendations (New England BioLabs, Ipswich, MA).

To generate anti-TrxA antibody, rTrxA protein was diluted to a concentration of 0.2 mg/ml and mixed 1:1 with TiterMax Gold adjuvant (Sigma-Aldrich, St. Louis, MO); BALB/c mice were vaccinated with two 50-μl subcutaneous (s.c.) injections at the base of the tail, resulting in a total dose of 10 μg rTrxA per mouse. A booster was administered 14 days after initial vaccination consisting of a single 50-μl s.c. injection of recombinant protein (5 μg). At 28 days after initial vaccination, mice were anesthetized and sera were collected.

**Generation of a targeted thioredoxin deletion mutant.** *A. baumannii* C179 DNA was extracted from a 3-ml volume of bacterial suspension using the Wizard Genomic DNA purification kit (Promega, Madison, WI). Using primer combinations Up_Fw/Up_Rv and Dn_Fw/Dn_Rv (Table 2) in combination with TaKaRa Ex Taq polymerase (Clontech, Mountain View, CA), a 973-bp region located directly upstream of trxA and a 1,326-bp product from extracted genomic DNA (Fig. S5, step 5). The PCR product was cloned into pGEM-T to generate pBPA001 (Fig. S5, step 6). An overnight culture of *A. baumannii* C179 was suspended in 100 μl sterile LB broth, and incubated at 37°C for 90 min. Bacteria were pelleted and washed in ice-cold 200 mM ice-cold RbCl, and 20 μl (1 μg/μl) pBPA002 was added with 50 μl cryotransformation buffer (10 mM HEPES, 0.1 M CaCl₂, 10 mM RbCl, 10% glycerol at pH 6.5) (50). The mixture was incubated on ice for 30 min and snap-frozen for 5 min in a dry-ice–ethanol bath. Bacteria were thawed at room temperature, suspended in 900 μl sterile LB, and incubated at 37°C for 90 min. Bacteria were pelleted and suspended in 100 μl sterile LB before plating on LB agar containing ethrythromycin. Isolated colonies were subcultured twice on selective agar and then three times on nonselective agar to ensure stable integration.

**Complementation of the deletion mutant.** The trxA gene was amplified from *A. baumannii* C177 by PCR utilizing the primer combination Up_Fw and a 2,326-bp product from extracted genomic DNA (Fig. S5, step 5). The PCR product was cloned into pGEM-T to generate pBPA003 (Fig. S5, step 5). A PCR product was produced using the Wizard SV gel cleanup kit (Promega, Madison, WI), and short overlap extension PCR (SOE-PCR) was performed under conditions described by Liu et al. (50), using primers Up_Fw and Dn_Rv and TaKaRa Ex Taq polymerase. The resulting PCR product (Fig. S5, step 2), containing a BamHI restriction site in place of the trxA gene, was subsequently ligated into pGEM-T Easy (Promega, Madison, WI) using T4 DNA ligase (Promega, Madison, WI) to make plasmid pBPA001. Transformants were identified through antibiotic selection on LB agar supplemented with 100 μg/ml ampicillin (Fig. S5, step 3). The erythromycin resistance cassette and promoter (*Femr*) were inserted from pEK887 by double digest with BglII and BamHI (50). In parallel, pBPA001 was subject to single restriction digest by BamHI. A 3:1 mix of *Femr* to pBPA001 was ligated to form pBPA002 and transformed into *E. coli* JM109. Transformants were selected by antibiotic selection on LB agar supplemented with 100 μg/ml ampicillin and 50 μg/ml erythromycin (Fig. S5, step 4). *A. baumannii* C179 was grown at 37°C to an OD₆₀₀ of 0.7 from a 1:100 dilution of an overnight broth culture. Once obtained, 5 ml was pelleted and washed in ice-cold 200 mM RbCl three times on ice for 5 min. Bacteria were suspended in 50 μl 200 mM ice-cold RbCl and 20 μl (1 μg/μl) pBPA002 was added with 50 μl cryotransformation buffer (10 mM HEPES, 0.1 M CaCl₂, 10 mM RbCl, 10% glycerol at pH 6.5) (50). The mixture was incubated on ice for 30 min and snap-frozen for 5 min in a dry-ice–ethanol bath. Bacteria were thawed at room temperature, suspended in 900 μl sterile LB, and incubated at 37°C for 90 min. Bacteria were pelleted and suspended in 100 μl sterile LB before plating on LB agar containing ethrythromycin. Isolated colonies were subcultured twice on selective agar and then three times on nonselective agar to ensure stable integration.

**Confirmation of genetic manipulation.** Growth was assessed through measurement of the optical density at 600 nm for *A. baumannii* C179, ΔtrxA, and ΔtrxA⁣⁺ strains grown in LB broth lacking antibiotics over 24 h. Differences in colony size for each strain were subsequently assessed following subculture on LB agar lacking antibiotics. Genetic manipulation was confirmed by Southern blot analysis. Genomic DNAs from C179, ΔtrxA, and ΔtrxA⁣⁺ strains were isolated using the GeneJet genomic DNA purification kit (Thermo Scientific, Rockford, IL), digested with XbaI or HindIII (New England BioLabs), and run on an 0.8% agarose gel at 16 V until completion. DNA was transferred to a nylon Biodyne B membrane (Thermo Scientific, Rockford, IL) and UV-cross-linked for 5 min. A DNA probe amplified from WT *A. baumannii* C179 genomic DNA using the DN_Fw/DN_Rv primer set was biotin labeled using the NorthSouth Southern blot hybridization and detection kit (Thermo Scientific, Rockport, ME). Hybridization and detection were performed using the NorthSouth chemiluminescent hybridization and detection kit (Thermo Scientific, Rockport, ME).
Fecal pellets were homogenized in sterile PBS to a concentration of 0.1 mg/ml, and 100 μl was spread onto CHROMagar Acinetobacter medium (DRG International, Inc., Springfield, NJ). Fecal pellets were collected prior to challenge to ensure that the mice were not precolonized with A. baumannii.

**Statistics.** For most experiments, statistical differences were assessed by one-way analysis of variance (ANOVA) with Holm-Sidak correction or the Welch t test. Differences in gene expression observed by RNA-seq were assessed by Student’s t test. For fecal shedding, statistical differences were assessed by both Kruskal-Wallis test with Dunn’s correction and Fisher’s exact test. All statistics and graphs were compiled using GraphPad Prism statistical software.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01298-18.

**FIG S1,** PDF file, 1.8 MB.

**FIG S2,** PDF file, 0.4 MB.

**FIG S3,** PDF file, 0.7 MB.

**FIG S4,** PDF file, 0.7 MB.

**FIG S5,** PDF file, 0.9 MB.

**ACKNOWLEDGMENTS**

This work received research support and funding provided by the Army Research Office of the Department of Defense (W911NF-11-1-0136), the Alvarez Graduate Research Education Excellence Fund and by an appointment to the Postgraduate Research Participation Program at the U.S. Army Institute of Surgical Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between U.S. Department of Energy and USAMRMC. Computational support from the UTSA Computational System Biology Core was funded by the National Institute on Minority Health and Health Disparities (G12MD007591) from the National Institutes of Health. This study also was supported with the Jane and Roland Blumberg Professorship in Biology for B. P. Arulanandam.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

**REFERENCES**

1. Antunes LC, Vispa P, Towner KJ. 2014. *Acinetobacter baumannii*: evolution of a global pathogen. Pathog Dis 71:292–301. https://doi.org/10.1111/2049-632X.12125.

2. Bergogne-Bézard E, Towner KJ. 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148–165.

3. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendia JL, Ortiz C, Cobacho AR. 1996. Bacteremia due to *Acinetobacter baumannii*: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026–1032. https://doi.org/10.1093/clinids/22.6.1026.

4. Dy ME, Nord JA, LaBombardi VJ, Kislak JW. 1999. The emergence of resistant strains of *Acinetobacter baumannii*: clinical and infection control implications. Infect Control Hosp Epidemiol 20:565–567. https://doi.org/10.1086/501673.

5. Fournier PE, Richet H. 2006. The epidemiology and control of *Acinetobacter baumannii* in healthcare facilities. Clin Infect Dis 42:692–699. https://doi.org/10.1086/500202.

6. Vila J, Martí S, Sánchez-Céspedes J. 2007. Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*. J Antimicrob Chemother 59:1210–1215. https://doi.org/10.1093/jac/dkl509.

7. Abbo A, Navon-Venezia S, Hammer-Munzt O, Krichali T, Siegman-Igra Y, Carmeli Y. 2005. Multidrug-resistant *Acinetobacter baumannii*. Emerg Infect Dis 11:22–29. https://doi.org/10.3201/eid1101.040001.

8. Anders MW, Ratnayake JH, Hanna PE, Fuchs JA. 1981. Thioredoxin-dependent sulfoxide reduction by rat renal cytosol. Drug Metab Dispos 9:307–310.

9. Dent LL, Marshall DR, Pratap S, Hulette RB. 2010. Multidrug resistant *Acinetobacter baumannii*: a descriptive study in a city hospital. BMC Infect Dis 10:196. https://doi.org/10.1186/1471-2334-10-196.

10. Hospenthal DR, Crouch HK, English JF, Leach F, Pool J, Conger NG, Whitman TJ, Wortmann GW, Robertson JL, Murray CK. 2011. Multidrug-resistant bacterial colonization of combat-injured personnel at admission to medical centers after evacuation from Afghanistan and Iraq. J Trauma 71:552–557. https://doi.org/10.1097/TA.0b013e31822118f6.

11. Latibeadiere R, Rosa R, Laowansiri P, Arheart K, Namias N, Munoz-Price LS. 2015. Surveillance cultures growing carbapenem-resistant *Acinetobacter baumannii* predict the development of clinical infections: a retrospective cohort study. Clin Infect Dis 60:415–422. https://doi.org/10.1093/cid/ciu847.

12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant
Kilian M, Thomsen B, Petersen TE, Bleeg HS. 1983. Occurrence and 
multiplication caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Clinic Infect Dis 28:1008–1011. https://doi.org/10.1086/214732.

Garmacho-Montoro J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barreiro-
Almodóvar AE, García-Garmendia JL, Bernal-Meza M, Gallego-Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant *Acineto-
acter baumannii* ventilator-associated pneumonia (VAP) with intrave-
nous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111–1118. https://doi.org/10.1086/374337.

Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, Richet H. 1998. Nosocomial *Acinetobacter baumannii* bacteremia: microbiological and clinical epidemiology. Ann Intern Med 129:182–189. https://doi.org/10.1073/pnas.199808010-0003.

Huddleston JR. 2014. Horizontal gene transfer in the human gastroin-
testinal tract: potential spread of antibiotic resistance genes. Infect Drug Resist 7:167–175. https://doi.org/10.2147/IDR.S48820.

Roy S, Viswanathan R, Singh A, Das P, Basu S. 2010. Gut colonization by 
*Acinetobacter baumannii* in neonates. Eur J Clin Microbiol Infect Dis 29:1495–1500. https://doi.org/10.1007/s10096-010-1030-z.

Thom KA, Hsiao WWL, Harris AD, Stine OC, Rasko DA, Johnson JK. 2010. Patients with *Acinetobacter baumannii* bloodstream infections are colo-
minated in the gastrointestinal tract with identical strains. Am J Infect Control 38:751–753. https://doi.org/10.1016/j.ajic.2010.03.005.

Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Domínguez MA, 
Johansen FE, Kaetzel CS. 2011. Regulation of the polymeric immuno-
globulin receptor and IgA transport: new advances in environmental 
immunity and mucosal homeostasis in the gut. Mucosal Immunol 4:598–602. https://doi.org/10.1038/mi.2011.37.

Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, 
Bettsholz C, Brandtzaeg P. 1999. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polycyclic 
immunoglobulin receptor/secretory component-deficient mice. J Exp Med 190:915–922. https://doi.org/10.1083/jem.190.9.915.

Hashim OH, Hassan H. 1991. Actions of three clodstral IgA proteases on 
distinct forms of immunoglobulin A molecules. Immunology 73: 
235–238.

Heck LW, Alarcon PG, Kulhavy RM, Moriha K, Russell MW, Mestecky J. 
1990. Degradation of IgA proteins by *Pseudomonas aeruginosa* elastase. J Immunol 144:2253–2257.

Kilian M, Thomsen B, Petersen TE, Bleeg HS. 1983. Occurrence and 
nature of bacterial IgA proteases. Ann N Y Acad Sci 409:612–624. 
https://doi.org/10.1111/j.1749-6632.1983.tb06903.x.

Kornfeld SJ, Plaut AG. 1981. Secretary immunology and the bacterial IgA proteases. Rev Infect Dis 3:521–534. https://doi.org/10.1093/clinids/3.3.521.

Windle HJ, Fox A, Ni Eidhin D, Kelleher D. 2000. The thioredoxin system of 
*Helicobacter pylori*. J Biol Chem 275:5081–5089. https://doi.org/10.1074/jbc.P27.5.5081.